» Articles » PMID: 27066457

Oncogenic Intra-p53 Family Member Interactions in Human Cancers

Overview
Journal Front Oncol
Specialty Oncology
Date 2016 Apr 12
PMID 27066457
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

The p53 gene family members p53, p73, and p63 display several isoforms derived from the presence of internal promoters and alternative splicing events. They are structural homologs but hold peculiar functional properties. p53, p73, and p63 are tumor suppressor genes that promote differentiation, senescence, and apoptosis. p53, unlike p73 and p63, is frequently mutated in cancer often displaying oncogenic "gain of function" activities correlated with the induction of proliferation, invasion, chemoresistance, and genomic instability in cancer cells. These oncogenic functions are promoted either by the aberrant transcriptional cooperation of mutant p53 (mutp53) with transcription cofactors (e.g., NF-Y, E2F1, Vitamin D Receptor, Ets-1, NF-kB and YAP) or by the interaction with the p53 family members, p73 and p63, determining their functional inactivation. The instauration of these aberrant transcriptional networks leads to increased cell growth, low activation of DNA damage response pathways (DNA damage response and DNA double-strand breaks response), enhanced invasion, and high chemoresistance to different conventional chemotherapeutic treatments. Several studies have clearly shown that different cancers harboring mutant p53 proteins exhibit a poor prognosis when compared to those carrying wild-type p53 (wt-p53) protein. The interference of mutantp53/p73 and/or mutantp53/p63 interactions, thereby restoring p53, p73, and p63 tumor suppression functions, could be among the potential therapeutic strategies for the treatment of mutant p53 human cancers.

Citing Articles

Covalent Modification of p53 by ()-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one.

Brown K, Robello M, Perciaccante A, Dinan J, Maity T, Lyons G ACS Pharmacol Transl Sci. 2024; 7(11):3559-3572.

PMID: 39539265 PMC: 11555513. DOI: 10.1021/acsptsci.4c00447.


p53 biology and reactivation for improved therapy in MDS and AML.

Zawacka J Biomark Res. 2024; 12(1):34.

PMID: 38481290 PMC: 10936007. DOI: 10.1186/s40364-024-00579-9.


The Important Role of Protein Kinases in the p53 Sestrin Signaling Pathway.

Gulow K, Tumen D, Kunst C Cancers (Basel). 2023; 15(22).

PMID: 38001650 PMC: 10670278. DOI: 10.3390/cancers15225390.


PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma.

Paz M, Ferretti G, Martins-Dinis M, Ferreira B, Faier-Pereira A, Barnoud T Front Mol Biosci. 2023; 10:1165132.

PMID: 37101558 PMC: 10123287. DOI: 10.3389/fmolb.2023.1165132.


Gain of Function (GOF) Mutant p53 in Cancer-Current Therapeutic Approaches.

Roszkowska K, Piecuch A, Sady M, Gajewski Z, Flis S Int J Mol Sci. 2022; 23(21).

PMID: 36362074 PMC: 9654280. DOI: 10.3390/ijms232113287.


References
1.
Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D . Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J. 2001; 20(15):4163-72. PMC: 149170. DOI: 10.1093/emboj/20.15.4163. View

2.
Xu-Monette Z, Zhang S, Li X, Manyam G, Wang X, Xia Y . p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function. Aging (Albany NY). 2016; 8(2):345-65. PMC: 4789587. DOI: 10.18632/aging.100898. View

3.
Blandino G, Dobbelstein M . p73 and p63: why do we still need them?. Cell Cycle. 2004; 3(7):886-94. View

4.
Gualberto A, Aldape K, Kozakiewicz K, Tlsty T . An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci U S A. 1998; 95(9):5166-71. PMC: 20232. DOI: 10.1073/pnas.95.9.5166. View

5.
Greenblatt M, BENNETT W, Hollstein M, Harris C . Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54(18):4855-78. View